Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party
Language English Country England, Great Britain Media print-electronic
Document type Journal Article
PubMed
25234166
DOI
10.1038/leu.2014.280
PII: leu2014280
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Transplantation, Autologous MeSH
- Databases, Factual MeSH
- Adult MeSH
- Transplantation, Homologous MeSH
- Cooperative Behavior MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Liver Neoplasms mortality pathology therapy MeSH
- Splenic Neoplasms mortality pathology therapy MeSH
- Follow-Up Studies MeSH
- Lymphoma, T-Cell, Peripheral mortality pathology therapy MeSH
- Recurrence MeSH
- Registries * MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Europe MeSH
The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.
EBMT Lymphoma Working Party Paris France
Gazi Universitesi Tip Fakultesi Ankara Turkey
Humanitas Cancer Center Rozzano Italy
Institut Paoli Calmettes Marseille France
Institute of Hematology and Blood Transfusion Prague Czech Republic
Pathodiagnostik Berlin Berlin Germany
See more in PubMed
J Clin Oncol. 2008 May 10;26(14):2264-71 PubMed
Leukemia. 2000 Jun;14(6):991-7 PubMed
Nat Rev Clin Oncol. 2009 Dec;6(12):707-17 PubMed
J Clin Oncol. 2008 Sep 1;26(25):4124-30 PubMed
Ann Oncol. 2009 Jun;20(6):1080-5 PubMed
Am J Clin Pathol. 2007 Jun;127(6):869-80 PubMed
J Clin Oncol. 2009 Aug 20;27(24):3951-8 PubMed
Blood. 2003 Dec 15;102(13):4261-9 PubMed
Leukemia. 2012 Mar;26(3):520-6 PubMed
